ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. (2016)
Attributed to:
CANCER: Trials with potential global reach and other challenging trials
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.cct.2016.10.004
PubMed Identifier: 27777129
Publication URI: http://europepmc.org/abstract/MED/27777129
Type: Journal Article/Review
Volume: 51
Parent Publication: Contemporary clinical trials
ISSN: 1551-7144